Annual Report FY2024-25
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare submitted its Annual Report for FY2024-25 along with the notice for its 38th Annual General Meeting, scheduled for September 23, 2025 via video conferencing. For FY25, the company reported consolidated revenue of Rs 1,30,957 lakhs, up 13% from Rs 1,15,977 lakhs in FY24, driven by strong growth in Formulations (+37%) and Biologics (+115%). EBITDA rose 35% to Rs 34,021 lakhs with margins expanding from 22% to 26%, while profit after tax jumped to Rs 7,829 lakhs from Rs 3,187 lakhs. The company successfully raised Rs 50,000 lakhs through a Qualified Institutional Placement and used part of the proceeds to pre-pay Non-Convertible Debentures of around Rs 45,000 lakhs, cutting net debt sharply from Rs 90,386 lakhs to Rs 55,770 lakhs and improving Net Debt/EBITDA from 5.8x to 1.6x.
Strong earnings growth, margin expansion, and significant balance sheet deleveraging are positive signals for shareholders. The cleaner capital structure and diversified growth across API, Formulations, Biologics, and CDMO segments position the company well, though investors should watch execution on R&D pipelines and regulatory milestones.